L
Laura Marandino
Researcher at University of Milan
Publications - 147
Citations - 1202
Laura Marandino is an academic researcher from University of Milan. The author has contributed to research in topics: Medicine & Internal medicine. The author has an hindex of 11, co-authored 48 publications receiving 549 citations. Previous affiliations of Laura Marandino include Catholic University of the Sacred Heart & University of Turin.
Papers
More filters
Journal ArticleDOI
Updated Results of PURE-01 with Preliminary Activity of Neoadjuvant Pembrolizumab in Patients with Muscle-invasive Bladder Carcinoma with Variant Histologies
Andrea Necchi,Daniele Raggi,Andrea Gallina,Russell Madison,Maurizio Colecchia,Roberta Lucianò,Rodolfo Montironi,Patrizia Giannatempo,Elena Farè,Filippo Pederzoli,Marco Bandini,Marco Bianchi,Renzo Colombo,Giorgio Gandaglia,Nicola Fossati,Laura Marandino,Umberto Capitanio,Federico Dehò,Siraj M. Ali,Jon Chung,Jeffrey S. Ross,Andrea Salonia,Alberto Briganti,Francesco Montorsi +23 more
TL;DR: The updated PURE-01 results confirm the activity of neoadjuvant pembrolizumab in MIBC and VH and provide a rationale for selecting patients according to these features instead of the histological bladder cancer subtypes.
Journal ArticleDOI
Risks from Deferring Treatment for Genitourinary Cancers: A Collaborative Review to Aid Triage and Management During the COVID-19 Pandemic.
Christopher J.D. Wallis,Giacomo Novara,Laura Marandino,Axel Bex,Ashish M. Kamat,R. Jeffrey Karnes,Todd M. Morgan,Nicolas Mottet,Silke Gillessen,Alberto Bossi,Morgan Rouprêt,Thomas Powles,Andrea Necchi,James W.F. Catto,Zachary Klaassen +14 more
TL;DR: Patients and clinicians should consider the oncologic risk of delayed cancer intervention versus the risks of COVID-19 to the patient, treating health care professionals, and the health care system.
Journal ArticleDOI
Impact of Molecular Subtyping and Immune Infiltration on Pathological Response and Outcome Following Neoadjuvant Pembrolizumab in Muscle-invasive Bladder Cancer.
Andrea Necchi,Daniele Raggi,Andrea Gallina,Jeffrey S. Ross,Jeffrey S. Ross,Elena Farè,Patrizia Giannatempo,Laura Marandino,Maurizio Colecchia,Roberta Lucianò,Marco Bianchi,Renzo Colombo,Andrea Salonia,Giorgio Gandaglia,Nicola Fossati,Marco Bandini,Filippo Pederzoli,Umberto Capitanio,Francesco Montorsi,Joep J. de Jong,Ryan Dittamore,Yang Liu,Elai Davicioni,Joost L. Boormans,Alberto Briganti,Peter C. Black,Ewan A. Gibb +26 more
TL;DR: Higher RNA-based immune signature scores were significantly associated with CR and numerically improved PFS outcomes after pembrolizumab, but not after NAC, emphasizing that RNA profiling is a potential tool for personalizing neoadjuvant therapy selection.
Journal ArticleDOI
Multiparametric Magnetic Resonance Imaging as a Noninvasive Assessment of Tumor Response to Neoadjuvant Pembrolizumab in Muscle-invasive Bladder Cancer: Preliminary Findings from the PURE-01 Study
Andrea Necchi,Marco Bandini,Giuseppina Calareso,Daniele Raggi,Filippo Pederzoli,Elena Farè,Maurizio Colecchia,Laura Marandino,Marco Bianchi,Andrea Gallina,Renzo Colombo,Nicola Fossati,Giorgio Gandaglia,Umberto Capitanio,Federico Dehò,Patrizia Giannatempo,Roberta Lucianò,Andrea Salonia,Russell Madison,Siraj M. Ali,Jon Chung,Jeffrey S. Ross,Jeffrey S. Ross,Alberto Briganti,Francesco Montorsi,Francesco De Cobelli,Antonella Messina +26 more
TL;DR: In post-pembrolizumab muscle-invasive bladder cancer, mpMRI sequence assessment had acceptable interobserver variability and represented the basis for the proposal of a radiological CR/NED status definition predicting the pT0 response to pembrolzumab.
Journal ArticleDOI
Does the administration of preoperative pembrolizumab lead to sustained remission post-cystectomy? First survival outcomes from the PURE-01 study☆
Marco Bandini,Ewan A. Gibb,Andrea Gallina,Daniele Raggi,Laura Marandino,Marco Bianchi,J.S. Ross,Maurizio Colecchia,Giorgio Gandaglia,Nicola Fossati,Filippo Pederzoli,Roberta Lucianò,Renzo Colombo,Andrea Salonia,Alberto Briganti,F. Montorsi,Andrea Necchi +16 more
TL;DR: The EFS results from PURE-01 revealed that the immunotherapy effect was maintained post-RC in most patients, and pembrolizumab compared favorably with neoadjuvant chemotherapy, irrespective of the biomarker status.